Medical treatments based on anamorelin
Methods of treating cancer related conditions using anamorelin are described.
1. A method of treating weight loss associated with cancer in a patient in need thereof comprising administering to said patient a therapeutically effective amount of anamorelin or a pharmaceutically acceptable salt thereof, wherein:
a) said patient has a body mass index of <20 kg/m 2 ; and
b) said patient has involuntary weight loss of >2% during the previous 6 months; and
said method increases the body weight of said patient.
2. The method of claim 1 , wherein said patient has an ECOG score of 0, 1, or 2.
3. The method of claim 1 , further for treating low quality of life as measured by FAACT in the anorexia/cachexia domain in said patient, wherein said patient has low quality of life as measured by FAACT in the anorexia/cachexia domain and said method improves said low quality of life.
4. The method of claim 1 , further for treating low quality of life as measured by FAACT in the anorexia/cachexia domain and low physical and functional well-being as measured by FAACT in the anorexia/cachexia domain in said patient, wherein:
a) said patient has low quality of life as measured by FAACT in the anorexia/cachexia domain; and
b) said patient has low physical and functional well-being as measured by FAACT in the anorexia/cachexia domain; and
said method improves said low quality of life and said low physical and functional well-being.
5. The method of claim 1 , wherein said patient has stage III unresectable or stage IV NSCLC.
6. The method of claim 1 , wherein said therapeutically effective amount comprises 100 mg of anamorelin or a pharmaceutically acceptable salt thereof once daily.
7. The method of claim 1 , wherein said therapeutically effective amount comprises 100 mg of anamorelin HCl based on the weight of the salt administered once daily.
8. The method of claim 4 , wherein said therapeutically effective amount comprises 100 mg of anamorelin or a pharmaceutically acceptable salt thereof once daily.
9. A method of treating weight loss associated with cancer, and anorexia symptoms as measured by FAACT in the anorexia/cachexia domain, in a patient in need thereof comprising administering to said patient a therapeutically effective amount of anamorelin or a pharmaceutically acceptable salt thereof, wherein:
a) said patient has a body mass index of <20 kg/m 2 ;
b) said patient has involuntary weight loss of >2% during the previous 6 months;
c) said method increases the body weight of said patient; and
d) said method improves said anorexia symptoms.
10. The method of claim 9 , wherein said patient has an ECOG score of 0, 1, or 2.
11. The method of claim 9 , further wherein said patient has low quality of life as measured by FAACT in the anorexia/cachexia domain and said method improves said quality of life.
12. The method of claim 9 , wherein said patient has stage III unresectable or stage IV NSCLC.
13. The method of claim 9 , wherein said therapeutically effective amount comprises 100 mg of anamorelin or a pharmaceutically acceptable salt thereof once daily.
14. The method of claim 9 , wherein said therapeutically effective amount comprises 100 mg of anamorelin HCl based on the weight of the salt administered once daily.
15. The method of claim 9 , wherein said patient has low physical and functional well-being as measured by FAACT in the anorexia/cachexia domain and said method improves said physical and functional well-being.
16. The method of claim 9 , wherein said improvement in anorexia symptoms is measured by a subset of FAACT in the anorexia/cachexia domain.
17. The method of claim 9 , wherein said improvement in anorexia symptoms is measured by the entire FAACT in the anorexia/cachexia domain.